Immunocore and MEPC have announced a 53,000 sq ft expansion at Milton Park in Oxfordshire.
MEPC will provide the drug developer with a purpose-built research laboratory and facilities. It has been based at Milton Park since 2000 and currently occupies 135,000 sq ft of laboratory and office space.
Immunocore will also take 48,000 sq ft in existing buildings at 96 Jubilee Avenue and 92 Park Drive on Milton Park.
MEPC chief executive James Dipple said: “The start of work on building 95 Park Drive brings the total new development under construction at Milton Park to over 160,000 sq ft.”
Planning consent for 95 Park Drive was obtained through a fast-track local development order on the park, which enables MEPC to secure consent for a wide range of development at Milton Park in just 10 days.
To send feedback, e-mail alex.peace@egi.co.uk or tweet @egalexpeace or @estatesgazette
